10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ANTH (Anthera) Stock Analysis
Buy, Hold or Sell?

Let's analyze Anthera together

I guess you are interested in Anthera Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Anthera’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Anthera’s Price Targets

I'm going to help you getting a better view of Anthera Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Anthera Pharmaceuticals Inc

I send you an email if I find something interesting about Anthera Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Anthera (30 sec.)










1.2. What can you expect buying and holding a share of Anthera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.21
Expected worth in 1 year
$-2.95
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-2.74
Return On Investment
-2,744,916.8%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anthera (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-16.34 - $1.24
Total Value Per Share
$-16.55 - $1.03

2.2. Growth of Anthera (5 min.)




Is Anthera growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.4m$12.4m-$17.9m-326.9%

How much money is Anthera making?

Current yearPrevious yearGrowGrow %
Making money-$16.9m-$53.6m$36.6m216.5%
Net Profit Margin0.0%-36,967.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Anthera (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anthera?

Welcome investor! Anthera's management wants to use your money to grow the business. In return you get a share of Anthera.

First you should know what it really means to hold a share of Anthera. And how you can make/lose money.

Speculation

The Price per Share of Anthera is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anthera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anthera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.21. Based on the TTM, the Book Value Change Per Share is $-0.69 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anthera.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.12-1,122,146.1%-1.12-1,122,146.1%-2.54-2,537,768.4%-1.67-1,668,417.4%-1.46-1,462,980.3%-1.59-1,592,668.7%
Usd Book Value Change Per Share-0.69-686,229.2%-0.69-686,229.2%-1.04-1,038,492.2%-0.04-41,177.6%-0.02-15,042.4%0.001,413.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.69-686,229.2%-0.69-686,229.2%-1.04-1,038,492.2%-0.04-41,177.6%-0.02-15,042.4%0.001,413.2%
Usd Price Per Share1.65-1.65-0.65-2.31-2.32-2.32-
Price to Earnings Ratio-1.47--1.47--0.26--1.73--1.84--1.43-
Price-to-Total Gains Ratio-2.40--2.40--0.63--0.04-0.37--0.16-
Price to Book Ratio-7.86--7.86-1.36--1.15--3.26--1.02-
Price-to-Total Gains Ratio-2.40--2.40--0.63--0.04-0.37--0.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.69-0.02
Usd Total Gains Per Share-0.69-0.02
Gains per Quarter (10000000 shares)-6,862,291.96-150,424.19
Gains per Year (10000000 shares)-27,449,167.85-601,696.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-27449168-274491780-601697-601707
20-54898336-548983460-1203394-1203404
30-82347504-823475140-1805090-1805101
40-109796671-1097966820-2406787-2406798
50-137245839-1372458500-3008484-3008495
60-164695007-1646950180-3610181-3610192
70-192144175-1921441860-4211877-4211889
80-219593343-2195933540-4813574-4813586
90-247042511-2470425220-5415271-5415283
100-274491679-2744916900-6016968-6016980

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%4.07.00.036.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%4.07.00.036.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Anthera Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.686-0.6860%-1.038+51%-0.041-94%-0.015-98%0.001-48658%
Book Value Per Share---0.210-0.2100%0.476-144%0.594-135%0.452-146%0.455-146%
Current Ratio--0.6770.6770%2.137-68%2.822-76%3.301-79%3.068-78%
Debt To Asset Ratio--2.4962.4960%0.469+433%1.047+138%1.079+131%1.152+117%
Debt To Equity Ratio----0%0.882-100%0.365-100%0.526-100%0.541-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--36223845.00036223845.0000%26834983.630+35%74337926.877-51%70984505.126-49%90846011.204-60%
Eps---1.122-1.1220%-2.538+126%-1.668+49%-1.463+30%-1.593+42%
Ev To Ebitda Ratio---1.362-1.3620%-0.472-65%-2.136+57%-2.225+63%-2.213+62%
Free Cash Flow Per Share---1.410-1.4100%-1.898+35%-1.497+6%-1.338-5%-1.472+4%
Free Cash Flow To Equity Per Share---0.712-0.7120%-0.997+40%-0.006-99%-0.172-76%-0.014-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.244----------
Intrinsic Value_10Y_min---16.336----------
Intrinsic Value_1Y_max---1.025----------
Intrinsic Value_1Y_min---1.548----------
Intrinsic Value_3Y_max---2.203----------
Intrinsic Value_3Y_min---4.756----------
Intrinsic Value_5Y_max---2.325----------
Intrinsic Value_5Y_min---8.053----------
Market Cap2617.930-1649900%43195845.00043195845.0000%16992983.630+154%60553593.543-29%60678905.126-29%60812157.763-29%
Net Profit Margin----0%-369.6760%-126.8790%-76.1270%-38.0640%
Operating Margin----0%-394.3240%-135.0980%-81.0590%-40.5290%
Operating Ratio----0%395.643-100%135.906-100%81.544-100%40.772-100%
Pb Ratio0.000+100%-7.861-7.8610%1.363-677%-1.145-85%-3.257-59%-1.023-87%
Pe Ratio0.000+100%-1.470-1.4700%-0.256-83%-1.725+17%-1.835+25%-1.430-3%
Price Per Share0.000-1649900%1.6501.6500%0.649+154%2.313-29%2.318-29%2.323-29%
Price To Free Cash Flow Ratio0.000+100%-1.171-1.1710%-0.342-71%-1.811+55%-1.913+63%-1.654+41%
Price To Total Gains Ratio0.000+100%-2.404-2.4040%-0.625-74%-0.044-98%0.367-756%-0.157-93%
Quick Ratio--0.4660.4660%1.962-76%2.670-83%3.197-85%3.344-86%
Return On Assets---4.611-4.6110%-2.284-50%-2.540-45%-3.438-25%-2.575-44%
Return On Equity----0%-4.2990%-1.7260%-1.4840%-1.3120%
Total Gains Per Share---0.686-0.6860%-1.038+51%-0.041-94%-0.015-98%0.001-48658%
Usd Book Value---5495000.000-5495000.0000%12470000.000-144%15544000.000-135%11825800.000-146%11920556.100-146%
Usd Book Value Change Per Share---0.686-0.6860%-1.038+51%-0.041-94%-0.015-98%0.001-48658%
Usd Book Value Per Share---0.210-0.2100%0.476-144%0.594-135%0.452-146%0.455-146%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--36223845.00036223845.0000%26834983.630+35%74337926.877-51%70984505.126-49%90846011.204-60%
Usd Eps---1.122-1.1220%-2.538+126%-1.668+49%-1.463+30%-1.593+42%
Usd Free Cash Flow---36900000.000-36900000.0000%-49685000.000+35%-39190666.667+6%-35020000.000-5%-38546207.900+4%
Usd Free Cash Flow Per Share---1.410-1.4100%-1.898+35%-1.497+6%-1.338-5%-1.472+4%
Usd Free Cash Flow To Equity Per Share---0.712-0.7120%-0.997+40%-0.006-99%-0.172-76%-0.014-98%
Usd Market Cap2617.930-1649900%43195845.00043195845.0000%16992983.630+154%60553593.543-29%60678905.126-29%60812157.763-29%
Usd Price Per Share0.000-1649900%1.6501.6500%0.649+154%2.313-29%2.318-29%2.323-29%
Usd Profit---16935000.000-16935000.0000%-53603000.000+217%-35150000.000+108%-33773200.000+99%-39431651.700+133%
Usd Revenue----0%145000.000-100%1110000.000-100%666000.000-100%333000.000-100%
Usd Total Gains Per Share---0.686-0.6860%-1.038+51%-0.041-94%-0.015-98%0.001-48658%
 EOD+2 -6MRQTTM+0 -0YOY+22 -113Y+11 -225Y+8 -2510Y+12 -21

3.3 Fundamental Score

Let's check the fundamental score of Anthera Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.466
Current Ratio (MRQ)Greater than10.677
Debt to Asset Ratio (MRQ)Less than12.496
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-4.611
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Anthera Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Anthera Pharmaceuticals Inc

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Fundamental data was last updated by Penke on 2025-06-27 00:15:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Anthera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Anthera to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-36,967.6%+36,967.6%
TTM-5Y-7,612.7%+7,612.7%
5Y-7,612.7%10Y-3,806.4%-3,806.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--88.2%+88.2%
TTM--141.5%+141.5%
YOY-36,967.6%-182.9%-36,784.7%
3Y-12,687.9%-247.7%-12,440.2%
5Y-7,612.7%-338.6%-7,274.1%
10Y-3,806.4%-473.1%-3,333.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Anthera is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Anthera to theΒ Biotechnology industry mean.
  • -461.1% Return on Assets means thatΒ Anthera generatedΒ $-4.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anthera Pharmaceuticals Inc:

  • The MRQ is -461.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -461.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-461.1%TTM-461.1%0.0%
TTM-461.1%YOY-228.4%-232.7%
TTM-461.1%5Y-343.8%-117.3%
5Y-343.8%10Y-257.5%-86.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-461.1%-11.1%-450.0%
TTM-461.1%-11.2%-449.9%
YOY-228.4%-11.0%-217.4%
3Y-254.0%-11.6%-242.4%
5Y-343.8%-11.8%-332.0%
10Y-257.5%-13.6%-243.9%
4.3.1.3. Return on Equity

Shows how efficient Anthera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Anthera to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Anthera generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-429.9%+429.9%
TTM-5Y-148.4%+148.4%
5Y-148.4%10Y-131.2%-17.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--12.8%+12.8%
TTM--14.2%+14.2%
YOY-429.9%-14.1%-415.8%
3Y-172.6%-16.6%-156.0%
5Y-148.4%-17.3%-131.1%
10Y-131.2%-19.4%-111.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Anthera Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Anthera is operatingΒ .

  • Measures how much profit Anthera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Anthera to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-39,432.4%+39,432.4%
TTM-5Y-8,105.9%+8,105.9%
5Y-8,105.9%10Y-4,052.9%-4,052.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--227.4%+227.4%
TTM--253.9%+253.9%
YOY-39,432.4%-201.7%-39,230.7%
3Y-13,509.8%-214.9%-13,294.9%
5Y-8,105.9%-339.9%-7,766.0%
10Y-4,052.9%-444.7%-3,608.2%
4.3.2.2. Operating Ratio

Measures how efficient Anthera is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY395.643-395.643
TTM-5Y81.544-81.544
5Y81.54410Y40.772+40.772
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.060-2.060
TTM-2.737-2.737
YOY395.6432.997+392.646
3Y135.9063.496+132.410
5Y81.5444.660+76.884
10Y40.7726.353+34.419
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Anthera Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anthera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.68Β means the company has $0.68 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.677. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.677. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.677TTM0.6770.000
TTM0.677YOY2.137-1.460
TTM0.6775Y3.301-2.624
5Y3.30110Y3.068+0.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6773.670-2.993
TTM0.6773.745-3.068
YOY2.1374.121-1.984
3Y2.8224.623-1.801
5Y3.3015.733-2.432
10Y3.0686.143-3.075
4.4.3.2. Quick Ratio

Measures if Anthera is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Anthera to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.47Β means the company can pay off $0.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.466. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.466. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.466TTM0.4660.000
TTM0.466YOY1.962-1.496
TTM0.4665Y3.197-2.731
5Y3.19710Y3.344-0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4662.906-2.440
TTM0.4663.128-2.662
YOY1.9623.786-1.824
3Y2.6704.308-1.638
5Y3.1975.703-2.506
10Y3.3446.411-3.067
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Anthera Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AntheraΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Anthera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.50Β means that Anthera assets areΒ financed with 249.6% credit (debt) and the remaining percentage (100% - 249.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 2.496. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.496. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.496TTM2.4960.000
TTM2.496YOY0.469+2.027
TTM2.4965Y1.079+1.417
5Y1.07910Y1.152-0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4960.328+2.168
TTM2.4960.356+2.140
YOY0.4690.335+0.134
3Y1.0470.339+0.708
5Y1.0790.350+0.729
10Y1.1520.383+0.769
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Anthera is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Anthera to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anthera Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.882-0.882
TTM-5Y0.526-0.526
5Y0.52610Y0.541-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.384-0.384
TTM-0.436-0.436
YOY0.8820.413+0.469
3Y0.3650.447-0.082
5Y0.5260.464+0.062
10Y0.5410.512+0.029
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Anthera generates.

  • Above 15 is considered overpriced butΒ always compareΒ Anthera to theΒ Biotechnology industry mean.
  • A PE ratio of -1.47 means the investor is paying $-1.47Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anthera Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.470. Based on the earnings, the company is expensive. -2
  • The TTM is -1.470. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-1.470+1.470
MRQ-1.470TTM-1.4700.000
TTM-1.470YOY-0.256-1.215
TTM-1.4705Y-1.835+0.365
5Y-1.83510Y-1.430-0.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.125+2.125
MRQ-1.470-2.027+0.557
TTM-1.470-2.541+1.071
YOY-0.256-3.670+3.414
3Y-1.725-3.716+1.991
5Y-1.835-6.057+4.222
10Y-1.430-6.591+5.161
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anthera Pharmaceuticals Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.171. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.171. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-1.171+1.171
MRQ-1.171TTM-1.1710.000
TTM-1.171YOY-0.342-0.829
TTM-1.1715Y-1.913+0.743
5Y-1.91310Y-1.654-0.259
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.030+3.030
MRQ-1.171-2.710+1.539
TTM-1.171-3.805+2.634
YOY-0.342-4.404+4.062
3Y-1.811-5.103+3.292
5Y-1.913-8.536+6.623
10Y-1.654-9.228+7.574
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Anthera is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -7.86 means the investor is paying $-7.86Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anthera Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is -7.861. Based on the equity, the company is expensive. -2
  • The TTM is -7.861. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-7.861+7.860
MRQ-7.861TTM-7.8610.000
TTM-7.861YOY1.363-9.224
TTM-7.8615Y-3.257-4.604
5Y-3.25710Y-1.023-2.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0001.900-1.900
MRQ-7.8611.861-9.722
TTM-7.8612.162-10.023
YOY1.3632.465-1.102
3Y-1.1452.527-3.672
5Y-3.2573.682-6.939
10Y-1.0234.351-5.374
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2017-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,673
Total Liabilities9,168
Total Stockholder Equity-5,495
 As reported
Total Liabilities 9,168
Total Stockholder Equity+ -5,495
Total Assets = 3,673

Assets

Total Assets3,673
Total Current Assets3,191
Long-term Assets482
Total Current Assets
Cash And Cash Equivalents 2,196
Other Current Assets 1,990
Total Current Assets  (as reported)3,191
Total Current Assets  (calculated)4,186
+/- 995
Long-term Assets
Property Plant Equipment 482
Long-term Assets  (as reported)482
Long-term Assets  (calculated)482
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,711
Long-term Liabilities4,457
Total Stockholder Equity-5,495
Total Current Liabilities
Accounts payable 1,832
Other Current Liabilities 2,879
Total Current Liabilities  (as reported)4,711
Total Current Liabilities  (calculated)4,711
+/-0
Long-term Liabilities
Other Liabilities 4,457
Long-term Liabilities  (as reported)4,457
Long-term Liabilities  (calculated)4,457
+/-0
Total Stockholder Equity
Common Stock14
Retained Earnings -434,428
Accumulated Other Comprehensive Income -14
Capital Surplus 428,586
Total Stockholder Equity (as reported)-5,495
Total Stockholder Equity (calculated)-5,842
+/- 347
Other
Cash and Short Term Investments 2,196
Common Stock Shares Outstanding 10,278
Liabilities and Stockholders Equity 3,673
Net Debt -2,196
Net Invested Capital -5,828
Net Tangible Assets -5,828
Net Working Capital -1,520
Preferred Stock Total Equity 333
Property Plant and Equipment Gross 482



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
> Total Assets 
0
0
6,193
8,034
5,889
65,263
69,493
26,445
37,417
3,490
48,125
23,471
3,673
3,67323,47148,1253,49037,41726,44569,49365,2635,8898,0346,19300
   > Total Current Assets 
0
0
6,150
7,999
3,823
65,246
67,977
24,753
35,946
3,022
47,862
22,708
3,191
3,19122,70847,8623,02235,94624,75367,97765,2463,8237,9996,15000
       Cash And Cash Equivalents 
0
0
153
7,895
3,803
40,030
65,624
19,431
35,946
2,639
46,951
20,843
2,196
2,19620,84346,9512,63935,94619,43165,62440,0303,8037,89515300
       Short-term Investments 
0
0
5,825
40
0
23,351
1,746
5,322
0
0
0
0
0
000005,3221,74623,3510405,82500
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
326
0
0
003260000000000
       Other Current Assets 
0
0
172
63
20
1,865
607
426
358
383
1,170
3,730
1,990
1,9903,7301,1703833584266071,865206317200
   > Long-term Assets 
0
0
43
36
2,066
17
1,516
1,692
1,471
468
263
763
482
4827632634681,4711,6921,516172,066364300
       Property Plant Equipment 
0
0
43
28
13
17
1,276
1,150
812
468
263
763
482
4827632634688121,1501,2761713284300
       Other Assets 
0
0
0
8
2,053
0
240
116
10,301
0
0
0
0
000010,30111624002,0538000
> Total Liabilities 
0
0
12,058
8,494
18,168
8,005
50,409
29,971
22,659
5,751
8,468
11,001
9,168
9,16811,0018,4685,75122,65929,97150,4098,00518,1688,49412,05800
   > Total Current Liabilities 
0
0
9,058
8,494
18,168
8,005
30,235
9,421
4,784
5,751
8,468
10,624
4,711
4,71110,6248,4685,7514,7849,42130,2358,00518,1688,4949,05800
       Short-term Debt 
0
0
0
0
13,130
0
4,157
9,329
2,777
0
0
0
0
00002,7779,3294,157013,1300000
       Accounts payable 
0
0
3,774
1,597
3,146
3,792
17,432
5,206
3,519
2,232
5,259
4,782
1,832
1,8324,7825,2592,2323,5195,20617,4323,7923,1461,5973,77400
       Other Current Liabilities 
0
0
5,284
6,897
1,892
4,214
8,646
-5,114
1,265
3,519
3,071
5,842
2,879
2,8795,8423,0713,5191,265-5,1148,6464,2141,8926,8975,28400
   > Long-term Liabilities 
0
0
3,000
0
0
0
20,174
20,550
17,875
2,232
5,397
377
4,457
4,4573775,3972,23217,87520,55020,1740003,00000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
4,457
4,457000000000000
> Total Stockholder Equity
0
0
-5,865
-460
-12,279
57,258
19,084
-3,526
14,758
-2,261
39,657
12,470
-5,495
-5,49512,47039,657-2,26114,758-3,52619,08457,258-12,279-460-5,86500
   Common Stock
0
0
1
1
10
33
41
79
19
23
40
6
14
146402319794133101100
   Retained Earnings Total Equity-434,428-407,55400000000000
   Accumulated Other Comprehensive Income -14-6000-17-29-510-1-200
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
411,364
428,586
428,586411,36400000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
0
0
29,058
52,558
120,447
162,919
220,051
252,837
301,946
314,527
391,648
411,404
428,600
428,600411,404391,648314,527301,946252,837220,051162,919120,44752,55829,05800



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2022-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue-
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense--
Operating Income-0
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense-0
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-0
EBIT - interestExpense = 0
0
0
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-0
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-
Tax Provision--
Net Income From Continuing Ops-0
Net Income-
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Technical Analysis of Anthera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anthera. The general trend of Anthera is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anthera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Anthera Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anthera Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Know someone who trades $ANTH? Share this with them.πŸ‘‡

Anthera Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anthera Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anthera Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAnthera Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anthera Pharmaceuticals Inc. The current adx is .

Anthera Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAnthera Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Stochastic Oscillator ChartAnthera Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAnthera Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAnthera Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Williams %R ChartAnthera Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Average True Range (ATR) ChartAnthera Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAnthera Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAnthera Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anthera Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Anthera Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anthera Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Anthera with someone you think should read this too:
  • Are you bullish or bearish on Anthera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anthera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anthera Pharmaceuticals Inc

I send you an email if I find something interesting about Anthera Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Anthera Pharmaceuticals Inc.

Receive notifications about Anthera Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.